title: Evaluation of the pituitary function with insulin tolerance (hypoglycaemia) testing: are there any differences using insulin lispro compared to regular insulin?
abstract: OBJECTIVE
  The insulin tolerance test (ITT) remains the gold standard for evaluating the pituitary function, but has potential risks when hypoglycaemia is induced. There are scarce data using short-acting insulin analogs for ITTs. This pilot study compares the effects of insulin lispro (LPI) with regular insulin (RGI) during an ITT.
  
  
  METHODS
  Patients with suspected hypopituitarism (n = 103) randomly received either LPI (n = 51) or RGI (n = 52).
  
  
  RESULTS
  All patients reported signs and symptoms when hypoglycaemia was induced. In the LPI group, hypoglycaemia occurred sooner (23.6 +/- 1.6 vs. 28.3 +/- 1.4 min, p < 0.05), and duration of hypoglycaemia (25.0 +/- 1.7 vs. 31.9 +/- 1.9 min, p < 0.05) and time for blood glucose levels to return to a 'safe' level (>3.3 mmol/l; 56.5 +/- 2.3 vs. 76.0 +/- 2.1 min, p < 0.001) were shorter as compared with the RGI group. No differences in peak growth hormone and cortisol levels were observed between the two groups.
  
  
  CONCLUSIONS
  Our data suggest that despite inducing similar symptomatology, LPI exerted a quicker onset and a shorter duration of hypoglycaemia as compared with RGI. Thus, using LPI might reduce the potential risks associated with an ITT by shortening the hypoglycaemic phase of the test.
authors.affiliation: Department of Endocrinology, Oregon Health and Science University, Portland, Oreg. 97239-3098 USA. yuenk@ohsu.edu
authors.forename: Kevin C J
authors.initials: KC
authors.lastname: Yuen
authors.forename: Rakesh
authors.initials: R
authors.lastname: Amin
authors.forename: Marie B
authors.initials: MB
authors.lastname: Cook
authors.forename: Sharon A
authors.initials: SA
authors.lastname: Rhoads
authors.forename: David M
authors.initials: DM
authors.lastname: Cook
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007003:Hypoglycemia / Q000139:chemically induced* / Q000503:physiopathology*; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000494:pharmacology; D007018:Hypopituitarism / Q000097:blood / Q000175:diagnosis / Q000503:physiopathology; D007328:Insulin / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000494:pharmacology; D061268:Insulin Lispro; D007333:Insulin Resistance / Q000502:physiology; D008297:Male; D010865:Pilot Projects; D010901:Pituitary Function Tests / Q000009:adverse effects*; D010902:Pituitary Gland / Q000187:drug effects / Q000503:physiopathology*; D012307:Risk Factors
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D061268:Insulin Lispro; D013006:Growth Hormone; D006854:Hydrocortisone